Laronib 25 mg (Larotrectinib)
Manufactured By
Everest Pharmaceuticals Ltd.
COMPOSITION
LARONIB 25 capsules: Each capsule contains Larotrectinib Sulfate INN equivalent to Larotrectinib 25 mg.
LARONIB 100 capsules: Each capsule contains Larotrectinib Sulfate INN equivalent to Larotrectinib 100 mg.
INDICATIONS AND USAGE
Solid Tumors
WARNING AND PRECAUTIONS
Neurotoxicity
Among the 176 patients who received Larotrectinib, neurologic adverse reactions of any grade occurred in 53% of patients, including Grade 3 and Grade 4 neurologic adverse reactions in 6% and 0.6% of patients, respectively. The majority
of neurologic adverse reactions occurred within the first three months of treatment (range: 1 day to years). Grade 3 neurologic adverse reactions included delirium (2%), dysarthria
